Sicart Associates LLC Sells 5,970 Shares of Guardant Health, Inc. (NASDAQ:GH)

Sicart Associates LLC decreased its position in Guardant Health, Inc. (NASDAQ:GH) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 140,333 shares of the company’s stock after selling 5,970 shares during the quarter. Guardant Health makes up approximately 1.5% of Sicart Associates LLC’s portfolio, making the stock its 28th largest position. Sicart Associates LLC’s holdings in Guardant Health were worth $4,287,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in GH. Fiduciary Alliance LLC increased its holdings in Guardant Health by 7.6% during the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock worth $363,000 after buying an additional 836 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Guardant Health during the 3rd quarter worth approximately $15,624,000. Exome Asset Management LLC raised its holdings in shares of Guardant Health by 13.7% in the 3rd quarter. Exome Asset Management LLC now owns 89,800 shares of the company’s stock worth $2,060,000 after purchasing an additional 10,800 shares during the period. Geode Capital Management LLC lifted its stake in Guardant Health by 1.1% in the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after purchasing an additional 29,686 shares during the last quarter. Finally, Pier Capital LLC grew its holdings in Guardant Health by 36.7% during the third quarter. Pier Capital LLC now owns 158,429 shares of the company’s stock valued at $3,634,000 after purchasing an additional 42,575 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of GH opened at $37.31 on Friday. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $39.29. The company has a market capitalization of $4.61 billion, a P/E ratio of -8.80 and a beta of 1.28. The firm’s 50 day simple moving average is $33.60 and its 200 day simple moving average is $28.90.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The company had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business’s revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.73) earnings per share. On average, equities analysts anticipate that Guardant Health, Inc. will post -3.44 earnings per share for the current year.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares in the company, valued at $93,660. This represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Meghan V. Joyce sold 2,896 shares of Guardant Health stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now owns 7,648 shares in the company, valued at approximately $228,675.20. This represents a 27.47 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 5,432 shares of company stock worth $175,423. 5.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

GH has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their price target on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Leerink Partners cut their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Sanford C. Bernstein reduced their target price on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group upped their price target on shares of Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Fifteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health currently has an average rating of “Buy” and an average target price of $40.60.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.